These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 19115412

  • 1. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
    Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, Walker PD.
    J Neurosci Res; 2009 May 15; 87(7):1645-58. PubMed ID: 19115412
    [Abstract] [Full Text] [Related]

  • 2. Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.
    Dupre KB, Ostock CY, George JA, Eskow Jaunarajs KL, Hueston CM, Bishop C.
    ACS Chem Neurosci; 2013 May 15; 4(5):747-60. PubMed ID: 23496922
    [Abstract] [Full Text] [Related]

  • 3. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
    Dupre KB, Eskow KL, Barnum CJ, Bishop C.
    Neuropharmacology; 2008 Dec 15; 55(8):1321-8. PubMed ID: 18824001
    [Abstract] [Full Text] [Related]

  • 4. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
    Dupre KB, Ostock CY, Eskow Jaunarajs KL, Button T, Savage LM, Wolf W, Bishop C.
    Exp Neurol; 2011 Jun 15; 229(2):288-99. PubMed ID: 21352823
    [Abstract] [Full Text] [Related]

  • 5. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
    Dupre KB, Eskow KL, Steiniger A, Klioueva A, Negron GE, Lormand L, Park JY, Bishop C.
    Psychopharmacology (Berl); 2008 Jul 15; 199(1):99-108. PubMed ID: 18545986
    [Abstract] [Full Text] [Related]

  • 6. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Meadows SM, Conti MM, Gross L, Chambers NE, Avnor Y, Ostock CY, Lanza K, Bishop C.
    Mov Disord; 2018 Nov 15; 33(11):1740-1749. PubMed ID: 30485908
    [Abstract] [Full Text] [Related]

  • 7. Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.
    Ostock CY, Dupre KB, Jaunarajs KL, Walters H, George J, Krolewski D, Walker PD, Bishop C.
    Neuropharmacology; 2011 Sep 15; 61(4):753-60. PubMed ID: 21635907
    [Abstract] [Full Text] [Related]

  • 8. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A.
    Neuropharmacology; 2015 Jun 15; 93():52-67. PubMed ID: 25645393
    [Abstract] [Full Text] [Related]

  • 9. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
    Lindenbach D, Dupre KB, Eskow Jaunarajs KL, Ostock CY, Goldenberg AA, Bishop C.
    Brain Res; 2013 Nov 06; 1537():327-39. PubMed ID: 24060645
    [Abstract] [Full Text] [Related]

  • 10. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    McCreary AC, Varney MA, Newman-Tancredi A.
    Neuropharmacology; 2016 Jun 06; 105():651-660. PubMed ID: 26777281
    [Abstract] [Full Text] [Related]

  • 11. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
    Iderberg H, Rylander D, Bimpisidis Z, Cenci MA.
    Exp Neurol; 2013 Dec 06; 250():116-24. PubMed ID: 24029003
    [Abstract] [Full Text] [Related]

  • 12. Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia.
    Meadows SM, Chambers NE, Conti MM, Bossert SC, Tasber C, Sheena E, Varney M, Newman-Tancredi A, Bishop C.
    Exp Neurol; 2017 Jun 06; 292():168-178. PubMed ID: 28342749
    [Abstract] [Full Text] [Related]

  • 13. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec 06; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 14. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
    Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A.
    Exp Neurol; 2015 Sep 06; 271():335-50. PubMed ID: 26037043
    [Abstract] [Full Text] [Related]

  • 15. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
    Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, Walker PD.
    Eur J Neurosci; 2006 May 06; 23(10):2669-76. PubMed ID: 16817869
    [Abstract] [Full Text] [Related]

  • 16. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Gerlach M, Bartoszyk GD, Riederer P, Dean O, van den Buuse M.
    J Neural Transm (Vienna); 2011 Dec 06; 118(12):1733-42. PubMed ID: 21253782
    [Abstract] [Full Text] [Related]

  • 17. Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.
    Ba M, Kong M, Ma G, Yang H, Lu G, Chen S, Liu Z.
    Brain Res; 2007 Jan 05; 1127(1):177-84. PubMed ID: 17113046
    [Abstract] [Full Text] [Related]

  • 18. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats.
    Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C.
    Synapse; 2009 Jul 05; 63(7):610-20. PubMed ID: 19309758
    [Abstract] [Full Text] [Related]

  • 19. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
    Conti MM, Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Dell'isola R, Katzman AC, Bishop C.
    Neuropharmacology; 2014 Feb 05; 77():1-8. PubMed ID: 24067924
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.